Cargando…

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP)

BACKGROUND: New regimens may provide better tolerability, convenience, and safety for nonoccupational human immunodeficiency virus (HIV) postexposure prophylaxis (PEP). For this reason, we evaluated the single-tablet regimen of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) for 28...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inciarte, Alexy, Ugarte, Ainoa, Martínez-Rebollar, María, Torres, Berta, Fernández, Emma, Berrocal, Leire, Laguno, Montserrat, De la Mora, Lorena, De Lazzari, Elisa, Callau, Pilar, Chivite, Iván, González-Cordón, Ana, Solbes, Estela, Rico, Verónica, Barrero, Laura, Blanco, José Luis, Martínez, Esteban, Ambrosioni, Juan, Mallolas, Josep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394723/ https://www.ncbi.nlm.nih.gov/pubmed/37539061 http://dx.doi.org/10.1093/ofid/ofad374

Ejemplares similares

Evolution of Risk Behaviors, Sexually Transmitted Infections and PrEP Care Continuum in a Hospital-Based PrEP Program in Barcelona, Spain: A Descriptive Study of the First 2 Years’ Experience
por: Ugarte, Ainoa, et al.
Publicado: (2022)

Chemsex Practices in PrEP: Beyond Addiction and Risk Toward a Healthy Sex Life—Baseline Experiences from a Hospital-Based PrEP Program in Barcelona, Spain
por: De La Mora, Lorena, et al.
Publicado: (2022)

Sex-based epidemiological and immunovirological characteristics of people living with HIV in current follow-up at a tertiary hospital: a comparative retrospective study, Catalonia, Spain, 1982 to 2020
por: Toyos, Sara, et al.
Publicado: (2023)

Do ART and Chemsex Drugs Get Along? Potential Drug–Drug Interactions in a Cohort of People Living with HIV Who Engaged in Chemsex: A Retrospective Observational Study
por: De La Mora, Lorena, et al.
Publicado: (2022)

Perception of quality of care using patient reported experience measures (PREMs) in a cohort of adults with HIV: A cross-sectional study
por: de Lazzari, Elisa, et al.
Publicado: (2022)

Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
por: Greaves, Wayne, et al.
Publicado: (2019)

Increasing of New CA-MRSA Infections Detected in people living with HIV Who Engage in Chemsex in Barcelona: An Ambispective Study
por: De La Mora, Lorena, et al.
Publicado: (2023)

Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study
por: Martínez-Rebollar, María, et al.
Publicado: (2021)

Correction to: Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study
por: Martínez-Rebollar, María, et al.
Publicado: (2022)

Doravirine/lamivudine/tenofovir disoproxil fumarate-induced hypertriglyceridemia in a newly diagnosed AIDS patient
por: Barchi, Virginia, et al.
Publicado: (2022)

LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
por: Kumar, Princy, et al.
Publicado: (2018)

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
por: Johnson, Margaret, et al.
Publicado: (2019)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
por: Devred, Inès, et al.
Publicado: (2023)

2548. Pharmacokinetic Analysis of Co-Administering Doravirine, Tenofovir Disoproxil Fumarate, Estradiol, and Spironolactone
por: Lam, Kevin, et al.
Publicado: (2023)

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations
por: Wong, Alexander, et al.
Publicado: (2019)

Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
por: Vaddady, Pavan, et al.
Publicado: (2020)

Context and Barriers to the Prescription of Nonoccupational Postexposure Prophylaxis Among HIV Medical Care Providers: National Internet-Based Observational Study in China
por: Ding, Haibo, et al.
Publicado: (2021)

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial
por: Orkin, Chloe, et al.
Publicado: (2019)

Human occupational and nonoccupational exposure to fibers.
por: Esmen, N A, et al.
Publicado: (1990)

Trace metals in occupationally and nonoccupationally exposed individuals.
por: Johnson, D E, et al.
Publicado: (1975)

Role of Predatory Mites in Persistent Nonoccupational Allergic Rhinitis
por: Poza Guedes, Paloma, et al.
Publicado: (2016)

Discussion Summary: Potential Hazards Related to Other Nonoccupational Exposures
Publicado: (1985)

Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine
por: Molina, Jean-Michel, et al.
Publicado: (2022)

Changes in Retinol-Binding Protein Concentrations and Thyroid Homeostasis with Nonoccupational Exposure to DDT
por: Delport, Rhena, et al.
Publicado: (2011)

A Review of Nonoccupational Pathways for Pesticide Exposure in Women Living in Agricultural Areas
por: Deziel, Nicole C., et al.
Publicado: (2015)

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial
por: Orkin, Chloe, et al.
Publicado: (2020)

Radiographic Evidence of Nonoccupational Asbestos Exposure from Processing Libby Vermiculite in Minneapolis, Minnesota
por: Alexander, Bruce H., et al.
Publicado: (2011)

Nonoccupational anthracofibrosis/anthracosilicosis from Ladakh in Jammu and Kashmir, India: A case series
por: Spalgais, Sonam, et al.
Publicado: (2015)

A Comparison of Self-Reported Nonoccupational Noise Exposure in a Large Cohort of Listeners
por: Adson, Kendell, et al.
Publicado: (2022)

Changes in weight and BMI with first-line doravirine-based therapy
por: Orkin, Chloe, et al.
Publicado: (2021)

Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen
por: Iannone, Valentina, et al.
Publicado: (2023)

Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model
por: Zizioli, Daniela, et al.
Publicado: (2023)

Postexposure Treatment of Marburg Virus Infection
por: Geisbert, Thomas W., et al.
Publicado: (2010)

Ribavirin for Lassa Fever Postexposure Prophylaxis
por: Hadi, Christiane M., et al.
Publicado: (2010)

The Traveling Libby Legacy: Minnesota Community Exhibits Nonoccupational Health Impacts Consistent with Asbestos Damage
por: Tillett, Tanya
Publicado: (2012)

546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration
por: Matthews, Randolph, et al.
Publicado: (2018)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development
por: Martin, Elizabeth Anne, et al.
Publicado: (2020)

Risks and Benefits of Preexposure and Postexposure Smallpox Vaccination
por: Meltzer, Martin I.
Publicado: (2003)

Rabies postexposure prophylaxis survey--Kentucky, 1994.
por: Auslander, M, et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_56tpvk2t7lv6b6t7aksm0h2up8